Abstracts tagged "treatment and Biologic agents"

Abstract Number: 1546 • 2019 ACR/ARP Annual Meeting
Effectiveness and Retention Rate of Secukinumab for Psoriatic Arthritis and Axial Spondyloarthritis: Real-life Data from the Italian LORHEN Registry
Ennio Giulio Favalli ¹, Antonio Marchesoni ¹, Silvia Balduzzi ², Carlomaurizio Montecucco ³, Claudia Lomater ⁴, Gloria Crepaldi ⁴, Silvia Tamanini ⁵, Chiara Bazzani ⁶, Enrico Fusaro ⁷, Marta Priora ⁷, Aurora Ianniello ⁸ and Roberto Caporali¹, ¹University of Milan, Department of Rheumatology, ASST Gaetano Pini-CTO, Milan, Lombardia, Italy, ²Department of Rheumatology, IRCCS Policlinico S. Matteo Foundation, University of Pavia, Pavia, Italy, Pavia, Lombardia, Italy, ³Department of Rheumatology, IRCCS Policlinico S. Matteo Foundation, University of Pavia, Pavia, Italy, Pavia, Italy, ⁴AO Ordine Mauriziano, SSD Reumatologia, Torino, Turin, Piemonte, Italy, ⁵ASST Spedali Civili and University of Brescia, Milan, Lombardia, Italy, ⁶Rheumatology and Clinical Immunology, Spedali Civili, Brescia, Italy, Brescia, Italy, ⁷A.O.U. Città della Salute e della Scienza di Torino, SC Reumatologia, Turin, Piemonte, Italy, ⁸Day Hospital Multidisciplinare PO SS. Trinità, Borgomanero, Borgomanero, Piemonte, Italy
Background/Purpose: Observational data on the use of secukinumab for the treatment of spondyloarthritides are still lacking. The aim of this study is to evaluate the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].